Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1653 entries
Sorted by: Best Match Show Resources per page
Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease.

Methods in molecular medicine

Miller GW, Wang YM, Gainetdinov RR, Caron MG.
PMID: 21318776
Methods Mol Med. 2001;62:179-90. doi: 10.1385/1-59259-142-6:179.

One of the most valuable methods for understanding the function of a particular protein is the generation of animals that have had the gene encoding for the protein of interest disrupted, commonly known as a "quo;knockout"quo; or null mutant....

Cite
Miller GW, Wang YM, Gainetdinov RR, et al. Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease. Methods Mol Med. 2001;62:179-90doi: 10.1385/1-59259-142-6:179.
Miller, G. W., Wang, Y. M., Gainetdinov, R. R., & Caron, M. G. (2001). Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease. Methods in molecular medicine, 62179-90. https://doi.org/10.1385/1-59259-142-6:179
Miller, G W, et al. "Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease." Methods in molecular medicine vol. 62 (2001): 179-90. doi: https://doi.org/10.1385/1-59259-142-6:179
Miller GW, Wang YM, Gainetdinov RR, Caron MG. Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease. Methods Mol Med. 2001;62:179-90. doi: 10.1385/1-59259-142-6:179. PMID: 21318776.
Copy Download .nbib Format: NLM
Antagonism of Low Dose Amphetamine Disruption of Latent Inhibition in Rats By Haloperidol, and By the 5Ht-3 Antagonist, Ondansetron: Warburton EC, Feldon J*, Weiner I*, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Dept of Psychology, Institute of Psychiatry, London, SE5 8AF and *Dept of Psychology, University of Tel Aviv, Israel.

Journal of psychopharmacology (Oxford, England)

[No authors listed]
PMID: 22291268
J Psychopharmacol. 1992 Jan;6(1):110. doi: 10.1177/026988119200600140.

No abstract available.

Cite
Antagonism of Low Dose Amphetamine Disruption of Latent Inhibition in Rats By Haloperidol, and By the 5Ht-3 Antagonist, Ondansetron: Warburton EC, Feldon J*, Weiner I*, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Dept of Psychology, Institute of Psychiatry, London, SE5 8AF and *Dept of Psychology, University of Tel Aviv, Israel. J Psychopharmacol. 1992;6(1):110doi: 10.1177/026988119200600140.
(1992). Antagonism of Low Dose Amphetamine Disruption of Latent Inhibition in Rats By Haloperidol, and By the 5Ht-3 Antagonist, Ondansetron: Warburton EC, Feldon J*, Weiner I*, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Dept of Psychology, Institute of Psychiatry, London, SE5 8AF and *Dept of Psychology, University of Tel Aviv, Israel. Journal of psychopharmacology (Oxford, England), 6(1), 110. https://doi.org/10.1177/026988119200600140
"Antagonism of Low Dose Amphetamine Disruption of Latent Inhibition in Rats By Haloperidol, and By the 5Ht-3 Antagonist, Ondansetron: Warburton EC, Feldon J*, Weiner I*, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Dept of Psychology, Institute of Psychiatry, London, SE5 8AF and *Dept of Psychology, University of Tel Aviv, Israel." Journal of psychopharmacology (Oxford, England) vol. 6,1 (1992): 110. doi: https://doi.org/10.1177/026988119200600140
Antagonism of Low Dose Amphetamine Disruption of Latent Inhibition in Rats By Haloperidol, and By the 5Ht-3 Antagonist, Ondansetron: Warburton EC, Feldon J*, Weiner I*, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Dept of Psychology, Institute of Psychiatry, London, SE5 8AF and *Dept of Psychology, University of Tel Aviv, Israel. J Psychopharmacol. 1992 Jan;6(1):110. doi: 10.1177/026988119200600140. PMID: 22291268.
Copy Download .nbib Format: NLM
20-year outcomes in adolescents who self-harm: a population-based cohort study.

The Lancet. Child & adolescent health

Borschmann R, Becker D, Coffey C, Spry E, Moreno-Betancur M, Moran P, Patton GC.
PMID: 30169168
Lancet Child Adolesc Health. 2017 Nov;1(3):195-202. doi: 10.1016/S2352-4642(17)30007-X. Epub 2017 Jul 08.

BACKGROUND: Little is known about the long-term psychosocial outcomes associated with self-harm during adolescence. We aimed to determine whether adolescents who self-harm are at increased risk of adverse psychosocial outcomes in the fourth decade of life, using data from...

Cite
Borschmann R, Becker D, Coffey C, et al. 20-year outcomes in adolescents who self-harm: a population-based cohort study. Lancet Child Adolesc Health. 2017;1(3):195-202doi: 10.1016/S2352-4642(17)30007-X.
Borschmann, R., Becker, D., Coffey, C., Spry, E., Moreno-Betancur, M., Moran, P., & Patton, G. C. (2017). 20-year outcomes in adolescents who self-harm: a population-based cohort study. The Lancet. Child & adolescent health, 1(3), 195-202. https://doi.org/10.1016/S2352-4642(17)30007-X
Borschmann, Rohan, et al. "20-year outcomes in adolescents who self-harm: a population-based cohort study." The Lancet. Child & adolescent health vol. 1,3 (2017): 195-202. doi: https://doi.org/10.1016/S2352-4642(17)30007-X
Borschmann R, Becker D, Coffey C, Spry E, Moreno-Betancur M, Moran P, Patton GC. 20-year outcomes in adolescents who self-harm: a population-based cohort study. Lancet Child Adolesc Health. 2017 Nov;1(3):195-202. doi: 10.1016/S2352-4642(17)30007-X. Epub 2017 Jul 08. PMID: 30169168.
Copy Download .nbib Format: NLM
Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs

McClellan KJ, Spencer CM.
PMID: 27521015
CNS Drugs. 1998 Apr;9(4):311-24. doi: 10.2165/00023210-199809040-00006.

SYNOPSIS: Modafinil promotes wakefulness through an as yet unknown mechanism of action. It significantly increases daytime sleep latency and reduces excessive daytime sleepiness (EDS) compared with placebo in patients with narcolepsy. However, the drug does not suppress cataplexy. Although...

Cite
McClellan KJ, Spencer CM. Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy. CNS Drugs. 1998;9(4):311-24doi: 10.2165/00023210-199809040-00006.
McClellan, K. J., & Spencer, C. M. (1998). Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy. CNS drugs, 9(4), 311-24. https://doi.org/10.2165/00023210-199809040-00006
McClellan, K J, and Spencer, C M. "Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy." CNS drugs vol. 9,4 (1998): 311-24. doi: https://doi.org/10.2165/00023210-199809040-00006
McClellan KJ, Spencer CM. Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy. CNS Drugs. 1998 Apr;9(4):311-24. doi: 10.2165/00023210-199809040-00006. PMID: 27521015.
Copy Download .nbib Format: NLM
The Disruptive Effect of Low Dose Amphetamine On Latent Inhibition in the Rat, Demonstrated in a Novel Within-Subject Paradigm: Young AMJ, Frangou S, Warburton EC, Joseph MH MRC Brain, Behaviour and Psychiatry Group, Departments of Psychology and Neuroscience, Institute of Psychiatry, London SE5 8AF.

Journal of psychopharmacology (Oxford, England)

[No authors listed]
PMID: 22291274
J Psychopharmacol. 1992 Jan;6(1):113. doi: 10.1177/026988119200600146.

No abstract available.

Cite
The Disruptive Effect of Low Dose Amphetamine On Latent Inhibition in the Rat, Demonstrated in a Novel Within-Subject Paradigm: Young AMJ, Frangou S, Warburton EC, Joseph MH MRC Brain, Behaviour and Psychiatry Group, Departments of Psychology and Neuroscience, Institute of Psychiatry, London SE5 8AF. J Psychopharmacol. 1992;6(1):113doi: 10.1177/026988119200600146.
(1992). The Disruptive Effect of Low Dose Amphetamine On Latent Inhibition in the Rat, Demonstrated in a Novel Within-Subject Paradigm: Young AMJ, Frangou S, Warburton EC, Joseph MH MRC Brain, Behaviour and Psychiatry Group, Departments of Psychology and Neuroscience, Institute of Psychiatry, London SE5 8AF. Journal of psychopharmacology (Oxford, England), 6(1), 113. https://doi.org/10.1177/026988119200600146
"The Disruptive Effect of Low Dose Amphetamine On Latent Inhibition in the Rat, Demonstrated in a Novel Within-Subject Paradigm: Young AMJ, Frangou S, Warburton EC, Joseph MH MRC Brain, Behaviour and Psychiatry Group, Departments of Psychology and Neuroscience, Institute of Psychiatry, London SE5 8AF." Journal of psychopharmacology (Oxford, England) vol. 6,1 (1992): 113. doi: https://doi.org/10.1177/026988119200600146
The Disruptive Effect of Low Dose Amphetamine On Latent Inhibition in the Rat, Demonstrated in a Novel Within-Subject Paradigm: Young AMJ, Frangou S, Warburton EC, Joseph MH MRC Brain, Behaviour and Psychiatry Group, Departments of Psychology and Neuroscience, Institute of Psychiatry, London SE5 8AF. J Psychopharmacol. 1992 Jan;6(1):113. doi: 10.1177/026988119200600146. PMID: 22291274.
Copy Download .nbib Format: NLM
N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks.

Addiction biology

Aerts LA, Mallaret M, Rigter H.
PMID: 20575841
Addict Biol. 2000 Jul 01;5(3):269-82. doi: 10.1111/j.1369-1600.2000.tb00191.x.

Abstract MBDB (N -methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane) is the alpha-ethyl homologue of MDMA (3,4-methylenedioxy-N-methylamphetamine). MBDB is metabolized and excreted similarly to MDMA: presumably, the majority of oral MBDB is excreted in urine unmetabolized.The main metabolic routes in man are thought to be...

Cite
Aerts LA, Mallaret M, Rigter H. N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addict Biol. 2000;5(3):269-82doi: 10.1111/j.1369-1600.2000.tb00191.x.
Aerts, L. A., Mallaret, M., & Rigter, H. (2000). N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addiction biology, 5(3), 269-82. https://doi.org/10.1111/j.1369-1600.2000.tb00191.x
Aerts, L A, et al. "N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks." Addiction biology vol. 5,3 (2000): 269-82. doi: https://doi.org/10.1111/j.1369-1600.2000.tb00191.x
Aerts LA, Mallaret M, Rigter H. N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addict Biol. 2000 Jul 01;5(3):269-82. doi: 10.1111/j.1369-1600.2000.tb00191.x. PMID: 20575841.
Copy Download .nbib Format: NLM
Psychostimulant drugs for cocaine dependence.

The Cochrane database of systematic reviews

Castells X, Cunill R, Pérez-Mañá C, Vidal X, Capellà D.
PMID: 27670244
Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380. doi: 10.1002/14651858.CD007380.pub4.

BACKGROUND: Cocaine dependence is a severe disorder for which no medication has been approved. Like opioids for heroin dependence, replacement therapy with psychostimulants could be an effective therapy for treatment.OBJECTIVES: To assess the effects of psychostimulants for cocaine abuse...

Cite
Castells X, Cunill R, Pérez-Mañá C, et al. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9:CD007380doi: 10.1002/14651858.CD007380.pub4.
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D. (2016). Psychostimulant drugs for cocaine dependence. The Cochrane database of systematic reviews, 9CD007380. https://doi.org/10.1002/14651858.CD007380.pub4
Castells, Xavier, et al. "Psychostimulant drugs for cocaine dependence." The Cochrane database of systematic reviews vol. 9 (2016): CD007380. doi: https://doi.org/10.1002/14651858.CD007380.pub4
Castells X, Cunill R, Pérez-Mañá C, Vidal X, Capellà D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380. doi: 10.1002/14651858.CD007380.pub4. PMID: 27670244; PMCID: PMC6457633.
Copy Download .nbib Format: NLM
Mobile Phone, Computer, and Internet Use Among Older Homeless Adults: Results from the HOPE HOME Cohort Study.

JMIR mHealth and uHealth

Raven MC, Kaplan LM, Rosenberg M, Tieu L, Guzman D, Kushel M.
PMID: 30530464
JMIR Mhealth Uhealth. 2018 Dec 10;6(12):e10049. doi: 10.2196/10049.

BACKGROUND: The median age of single homeless adults is approximately 50 years. Older homeless adults have poor social support and experience a high prevalence of chronic disease, depression, and substance use disorders. Access to mobile phones and the internet...

Cite
Raven MC, Kaplan LM, Rosenberg M, et al. Mobile Phone, Computer, and Internet Use Among Older Homeless Adults: Results from the HOPE HOME Cohort Study. JMIR Mhealth Uhealth. 2018;6(12):e10049doi: 10.2196/10049.
Raven, M. C., Kaplan, L. M., Rosenberg, M., Tieu, L., Guzman, D., & Kushel, M. (2018). Mobile Phone, Computer, and Internet Use Among Older Homeless Adults: Results from the HOPE HOME Cohort Study. JMIR mHealth and uHealth, 6(12), e10049. https://doi.org/10.2196/10049
Raven, Maria C, et al. "Mobile Phone, Computer, and Internet Use Among Older Homeless Adults: Results from the HOPE HOME Cohort Study." JMIR mHealth and uHealth vol. 6,12 (2018): e10049. doi: https://doi.org/10.2196/10049
Raven MC, Kaplan LM, Rosenberg M, Tieu L, Guzman D, Kushel M. Mobile Phone, Computer, and Internet Use Among Older Homeless Adults: Results from the HOPE HOME Cohort Study. JMIR Mhealth Uhealth. 2018 Dec 10;6(12):e10049. doi: 10.2196/10049. PMID: 30530464; PMCID: PMC6305882.
Copy Download .nbib Format: NLM
Substance Abuse and the HIV Situation in Malaysia.

Journal of food and drug analysis

Singh D, Chawarski MC, Schottenfeld R, Vicknasingam B.
PMID: 25278737
J Food Drug Anal. 2013 Dec;21(4):S46-S51. doi: 10.1016/j.jfda.2013.09.033.

Heroin continues to be the main drug used in Malaysia, while amphetamine-type stimulants (ATS) have been recently identified as a growing problem. A cumulative total of 300,241 drug users were detected between 1988 and 2006. It is also estimated...

Cite
Singh D, Chawarski MC, Schottenfeld R, et al. Substance Abuse and the HIV Situation in Malaysia. J Food Drug Anal. 2013;21(4):S46-S51doi: 10.1016/j.jfda.2013.09.033.
Singh, D., Chawarski, M. C., Schottenfeld, R., & Vicknasingam, B. (2013). Substance Abuse and the HIV Situation in Malaysia. Journal of food and drug analysis, 21(4), S46-S51. https://doi.org/10.1016/j.jfda.2013.09.033
Singh, Darshan, et al. "Substance Abuse and the HIV Situation in Malaysia." Journal of food and drug analysis vol. 21,4 (2013): S46-S51. doi: https://doi.org/10.1016/j.jfda.2013.09.033
Singh D, Chawarski MC, Schottenfeld R, Vicknasingam B. Substance Abuse and the HIV Situation in Malaysia. J Food Drug Anal. 2013 Dec;21(4):S46-S51. doi: 10.1016/j.jfda.2013.09.033. PMID: 25278737; PMCID: PMC4179250.
Copy Download .nbib Format: NLM
Correction: Hoops et al., Dopamine Development in the Mouse Orbital Prefrontal Cortex is Protracted and Sensitive to Amphetamine in Adolescence (eNeuro January/February 2018, 5(1) e0372-17.2017 1-9 https://doi.org/10.1523/ENEURO.0372-17.2017.

eNeuro

[No authors listed]
PMID: 29488511
eNeuro. 2018 Feb 26;5(1). doi: 10.1523/ENEURO.0026-18.2018. eCollection 2018.

[This corrects the article DOI: 10.1523/ENEURO.0372-17.2017.][This corrects the article DOI: 10.1523/ENEURO.0372-17.2017.].

Cite
Correction: Hoops et al., Dopamine Development in the Mouse Orbital Prefrontal Cortex is Protracted and Sensitive to Amphetamine in Adolescence (eNeuro January/February 2018, 5(1) e0372-17.2017 1-9 https://doi.org/10.1523/ENEURO.0372-17.2017. eNeuro. 2018;5(1)doi: 10.1523/ENEURO.0026-18.2018.
(2018). Correction: Hoops et al., Dopamine Development in the Mouse Orbital Prefrontal Cortex is Protracted and Sensitive to Amphetamine in Adolescence (eNeuro January/February 2018, 5(1) e0372-17.2017 1-9 https://doi.org/10.1523/ENEURO.0372-17.2017. eNeuro, 5(1), . https://doi.org/10.1523/ENEURO.0026-18.2018
"Correction: Hoops et al., Dopamine Development in the Mouse Orbital Prefrontal Cortex is Protracted and Sensitive to Amphetamine in Adolescence (eNeuro January/February 2018, 5(1) e0372-17.2017 1-9 https://doi.org/10.1523/ENEURO.0372-17.2017." eNeuro vol. 5,1 (2018). doi: https://doi.org/10.1523/ENEURO.0026-18.2018
Correction: Hoops et al., Dopamine Development in the Mouse Orbital Prefrontal Cortex is Protracted and Sensitive to Amphetamine in Adolescence (eNeuro January/February 2018, 5(1) e0372-17.2017 1-9 https://doi.org/10.1523/ENEURO.0372-17.2017. eNeuro. 2018 Feb 26;5(1). doi: 10.1523/ENEURO.0026-18.2018. eCollection 2018. PMID: 29488511; PMCID: PMC5826098.
Copy Download .nbib Format: NLM
Evaluation of Attention-Deficit/Hyperactivity Disorder Medications, Externalizing Symptoms, and Suicidality in Children.

JAMA network open

Shoval G, Visoki E, Moore TM, DiDomenico GE, Argabright ST, Huffnagle NJ, Alexander-Bloch AF, Waller R, Keele L, Benton TD, Gur RE, Barzilay R.
PMID: 34086035
JAMA Netw Open. 2021 Jun 01;4(6):e2111342. doi: 10.1001/jamanetworkopen.2021.11342.

IMPORTANCE: Childhood suicidality (ie, suicidal ideation or attempts) rates are increasing, and attention-deficit/hyperactivity disorder (ADHD) and externalizing symptoms are common risk factors associated with suicidality. More data are needed to describe associations of ADHD pharmacotherapy with childhood suicidality.OBJECTIVE: To...

Cite
Shoval G, Visoki E, Moore TM, et al. Evaluation of Attention-Deficit/Hyperactivity Disorder Medications, Externalizing Symptoms, and Suicidality in Children. JAMA Netw Open. 2021;4(6):e2111342doi: 10.1001/jamanetworkopen.2021.11342.
Shoval, G., Visoki, E., Moore, T. M., DiDomenico, G. E., Argabright, S. T., Huffnagle, N. J., Alexander-Bloch, A. F., Waller, R., Keele, L., Benton, T. D., Gur, R. E., & Barzilay, R. (2021). Evaluation of Attention-Deficit/Hyperactivity Disorder Medications, Externalizing Symptoms, and Suicidality in Children. JAMA network open, 4(6), e2111342. https://doi.org/10.1001/jamanetworkopen.2021.11342
Shoval, Gal, et al. "Evaluation of Attention-Deficit/Hyperactivity Disorder Medications, Externalizing Symptoms, and Suicidality in Children." JAMA network open vol. 4,6 (2021): e2111342. doi: https://doi.org/10.1001/jamanetworkopen.2021.11342
Shoval G, Visoki E, Moore TM, DiDomenico GE, Argabright ST, Huffnagle NJ, Alexander-Bloch AF, Waller R, Keele L, Benton TD, Gur RE, Barzilay R. Evaluation of Attention-Deficit/Hyperactivity Disorder Medications, Externalizing Symptoms, and Suicidality in Children. JAMA Netw Open. 2021 Jun 01;4(6):e2111342. doi: 10.1001/jamanetworkopen.2021.11342. PMID: 34086035; PMCID: PMC8178707.
Copy Download .nbib Format: NLM
Othello Syndrome: Delusional Disorder - Jealous Type ≠ Violence.

CNS spectrums

Ahn ES, Hobbs JA.
PMID: 34127129
CNS Spectr. 2021 Apr;26(2):160-161. doi: 10.1017/S1092852920002588.

BACKGROUND: Othello syndrome, also known as morbid jealousy, pathological jealousy, and conjugal paranoia, is a rare delusional disorder related to partner's infidelity. There are no large scale or comprehensive studies on delusional jealousy, and only few case reports and...

Cite
Ahn ES, Hobbs JA. Othello Syndrome: Delusional Disorder - Jealous Type ≠ Violence. CNS Spectr. 2021;26(2):160-161doi: 10.1017/S1092852920002588.
Ahn, E. S., & Hobbs, J. A. (2021). Othello Syndrome: Delusional Disorder - Jealous Type ≠ Violence. CNS spectrums, 26(2), 160-161. https://doi.org/10.1017/S1092852920002588
Ahn, Elizabeth Soyeon, and Hobbs, Jacqueline A. "Othello Syndrome: Delusional Disorder - Jealous Type ≠ Violence." CNS spectrums vol. 26,2 (2021): 160-161. doi: https://doi.org/10.1017/S1092852920002588
Ahn ES, Hobbs JA. Othello Syndrome: Delusional Disorder - Jealous Type ≠ Violence. CNS Spectr. 2021 Apr;26(2):160-161. doi: 10.1017/S1092852920002588. PMID: 34127129.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1653 entries